Yaogen Chen, Chairman of Yatai Pharmaceutical, added: "This is a natural progression for Zhejiang Yatai and Benchmark Botanics as Benchmark's team already have experience in growing, cultivating and processing medical cannabis. We share the same principles as well as a philosophy rooted in science and geared for the production of unique, safe, and quality products. We've already established a multi-year plan and we're preparing our fully-equipped, state-of-the-art facility in Canada to capitalize the medical applications of CBD."
The companies plan to establish a new joint venture company in Canada to fully integrate Zhejiang Yatai 's advantages in drug research and development, production and sales in the medical field and Benchmark's advantages in cannabis cultivation and extraction. All intellectual property developed in the research process in Canada will be owned by both companies, with commercialization planned in the countries where cannabis products are legal.
It’s been easy enough to sell all day, which is unusual as usually this quickly goes NT when there is any substantial sells around. The last 1m showing is probs a buy given all buys at the time we’re the same price.